公司资料
Addex Therapeutics 股价、新闻与催化剂
- 股票代码:
- ADXN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Switzerland and trades in the U
股票表现
5.70 USD (-4.20%)
收盘价
最后更新: 2026年8月17日
8.1M USD
市值
股价为何变动
Current closing-price context is not available for ADXN.
公司概览
Allosteric Modulator Developer
Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders. Its strategy combines internally controlled programs, partnered assets, and economic exposure to a broader pipeline advanced through the Neurosterix spinout.
Internally Controlled Programs
Lead candidate dipraglurant is an mGlu5 negative allosteric modulator with potential applications in recovery from brain injury, stroke, and traumatic brain injury. Addex also has a GABAB positive allosteric modulator program for chronic cough.
Partnered Development Model
Indivior is developing an Addex-originated GABAB PAM for substance use disorders. This partnership model allows Addex to retain program economics while external collaborators fund and operate selected development programs.
Neurosterix Exposure
Addex holds a 20% interest in Neurosterix, which is advancing M4 PAM and mGlu7 NAM programs for schizophrenia, psychosis, mood disorders, and other central nervous system conditions.
未来催化剂
- Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。